Eli Lilly and Company
LLYNYSE
USReal-Time Price
USReal-Time Price$1,240.34USD
-16.69 (-1.33%)Today
$1,257.31+16.97 (+1.37%)Pre-Market7:38 AM ET
BTI Score
Near Future
67
Long Term
70
BTI Fair Market Cap
$471.53B
+147.62% vs fair
Healthcare & Pharma
High Risk
Eli Lilly and Company (LLY) Stock Analysis
BTI's proprietary analysis of Eli Lilly and Company (LLY): overall score, long- and short-term outlook, risk rating and fair-value verdict based on fundamentals, valuation and momentum.
Major-Firm Consensus
Strong Buy
Filtered to 36 major global investment banks
Buy
31
Hold
4
Sell
1
Price Target Consensus
High
$1600.00
Consensus
$1328.00
Low
$930.00
Current
$1240.34
Upside: +7.1%
Target Trend
Last Month— (0)
Last Quarter— (0)
Last Year— (0)
Ratings History — Major Investment Banks
| Firm | Rating | Action | Previous | Price Target | Upside | Date |
|---|---|---|---|---|---|---|
| Citi | Buy | Maintains | — | $1600.00 | +29.0% | Oct 20, 2026 |
| Barclays | Buy | Maintains | — | $1400.00 | +12.9% | Oct 19, 2026 |
| Bank of America Securities | Buy | Reiterates | — | — | — | Oct 19, 2026 |
| RBC Capital | Buy | Maintains | — | $1500.00 | +20.9% | Oct 17, 2026 |
| Wells Fargo | Buy | Maintains | — | $1330.00 | +7.2% | Oct 15, 2026 |
| BMO Capital | Buy | Maintains | — | $1400.00 | +12.9% | Oct 12, 2026 |
| J.P. Morgan | Buy | Maintains | — | $1500.00 | +20.9% | Oct 9, 2026 |
| Cantor Fitzgerald | Buy | Reiterates | — | — | — | Oct 8, 2026 |
Annual Analyst Estimates
| Fiscal Year | Revenue Avg | Revenue Range | EPS Avg | EPS Range | Analysts |
|---|---|---|---|---|---|
| FY 2026 | $88.55B | — – — | $35.22 | — – — | — |
| FY 2027 | $102.30B | — – — | $47.48 | — – — | — |
Want deeper AI-powered analysis?
Get BTI AI's full investment thesis, valuation models, and risk assessment for LLY.